Posted by Michael Wonder on 05 Sep 2024
US FDA approves FoundationOne CDx and FoundationOne Liquid CDx as companion diagnostics for Lynparza (olaparib) in combination with abiraterone for patients with BRCA mutated metastatic castration-resistant prostate cancer
3 September 2024 - Foundation Medicine’s tissue and liquid biopsy tests can now be used to identify more patients who could benefit from Lynparza in combination with abiraterone.
Foundation Medicine today announced that it has received approval from the US FDA for FoundationOne CDx and FoundationOne Liquid CDx to be used as companion diagnostics for AstraZeneca’s and Merck’s Lynparza (olaparib) in combination with abiraterone and prednisone or prednisolone for the treatment of adult patients with deleterious or suspected deleterious BRCA mutated metastatic castration-resistant prostate cancer.
